RecruitingPhase 2NCT06931652
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
Studying Primary central nervous system lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Lymphoma Academic Research Organisation
- Principal Investigator
- Hervé Pr. Ghesquieres, MDHCL - Hôpital Lyon Sud - Service d'Hématologie - 165 Chemin du Grand Revoyet, 69310 Pierre-Bénite - France
- Intervention
- Epcoritamab(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (13)
- INSTITUT BERGONIE - Service d'Oncologie Médicale, Bordeaux, France
- INSTITUT D'HEMATOLOGIE DE BASSE NORMANDIE - Service Hématologie, Caen, France
- CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique, Clermont-Ferrand, France
- CHU DE LILLE - HOPITAL CLAUDE HURIEZ - Service des Maladies du Sang, Lille, France
- CHR DE MARSEILLE - CHU TIMONE - Service de Neuro-Oncologie, Marseille, France
- CHRU DE NANCY - HOPITAL CENTRAL - Service de Neurologie, Nancy, France
- GHU PITIE-SALPETRIERE - CHARLES FOIX - Service Neurologie, Paris, France
- HOPITAL DE LA PITIE SALPETRIERE - Service Hématologie Clinique, Paris, France
- CHU LYON-SUD - Hématologie Clinique, Pierre-Bénite, France
- CHU PONTCHAILLOU - Hématologie Clinique, Rennes, France
- INSTITUT CURIE - SITE SAINT-CLOUD - Service Hématologie, Saint-Cloud, France
- IUCT ONCOPOLE - Service Hématologie, Toulouse, France
- CHU BRETONNEAU - Service Cancérologie - Hématologie et Thérapie Cellulaire, Tours, France
Collaborators
AbbVie
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06931652 on ClinicalTrials.govOther trials for Primary central nervous system lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07104032IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)Ono Pharmaceutical Co. Ltd
- RECRUITINGPHASE2NCT07416890Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaZhejiang Cancer Hospital
- RECRUITINGPHASE2NCT07410520PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.The First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE2NCT07350850A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)Tongji Hospital
- RECRUITINGPHASE2NCT07062627Anbalcabtagene Autoleucel in Relapsed/Refractory CNS LymphomaHyungwoo Cho
- RECRUITINGPHASE2NCT07015242A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE1NCT07082868A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06922604Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System LymphomaCity of Hope Medical Center
See all trials for Primary central nervous system lymphoma →